Middle East Fertility Society Journal
Middle East Fertility Society
Vol. 10, No. 1, 2005, pp. 49-54
Bioline Code: mf05009
Full paper language: English
Document type: Research Article
Document available free of charge
Middle East Fertility Society Journal, Vol. 10, No. 1, 2005, pp. 49-54
© Copyright 2005 - Middle East Fertility Society
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis|
Amira Badrawi, Hesham Al-Inany, Mahmoud Hussein, Salah Zaki, Abdel Maguid Ramzy
Objective: GnRH antagonists have been introduced into clinical practice as an attractive alternative to GnRH long protocol under the concept of a patient friendly medication. We wished to evaluate the cost effectiveness of a human menopausal gonadotropin (hMG) / GnRH antagonist flexible protocol versus a long GnRH agonist / hMG protocol.
Design: single center randomized controlled trial using sealed envelopes as a method for randomization.
Materials and methods: One hundred women undergoing ICSI were randomized to receive either hMG/GnRH agonist long protocol (group I) or hMG/GnRH antagonist when follicle reaches 15 mm (group II).
Results: Two cases had premature LH surge in group II. Fifteen cases (30%) got pregnant in the first group as compared to 12 cases (24%) in the second group. The difference was statistically non-significant. The mean cost of medications per cycle was estimated to be $608 (3740 Egyptian Pounds) in the hMG/antagonist group, while it was $680 (4180 E.P) in the long GnRH agonist protocol treated group. This difference was statistically. However, the total cost per pregnancy was $6531 (40166 EP) in the hMG/antagonist protocol and $5008 (30800 EP) in the GnRH-a/hMG protocol which is statistically significant.
Conclusion: the use of the hMG/antagonist protocol is not a cost effective strategy although it provides short and simple stimulation protocol.
GnRH antagonist, Flexible, agonist, ovarian stimulation, ICSI
Alternative site location: http://www.mefsjournal.org